Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 9/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.45 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SCN4A | P35499 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29288485 | 0.84 | HSD17B3 (0.39) | NOTUMHSD17B3P2RX4P2RX1P2RX3 | |
| SCHEMBL3375661 | 0.84 | P2RX4 (0.44) | HSD17B3P2RX4P2RX1P2RX3P2RX7 | |
| SCHEMBL29376182 | 0.84 | P2RX4 (0.44) | HSD17B3P2RX4P2RX1P2RX3P2RX7 | |
| SCHEMBL1286806 | 0.82 | LMNA (0.55) | HSD17B3P2RX4P2RX1P2RX3P2RX7 | |
| SCHEMBL3838005 | 0.81 | NOTUM (0.49) | NOTUMHSD17B3 | |
| SCHEMBL27785934 | 0.81 | P2RX4 (0.58) | P2RX4P2RX1P2RX3P2RX7SMN1; SMN2 | |
| SCHEMBL3241414 | 0.81 | P2RX4 (0.42) | HSD17B3P2RX4P2RX1P2RX3P2RX7 | |
| Hydrochloric Acid SCHEMBL28145471 | 0.81 | LMNA (0.53) | HSD17B3P2RX4P2RX1P2RX3P2RX7 | |
| SCHEMBL8705933 | 0.79 | P2RX4 (0.57) | P2RX4SMN1; SMN2NPSR1LMNATSHR | |
| SCHEMBL7035186 | 0.79 | LMNA (0.47) | P2RX4P2RX1P2RX3P2RX7PTBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114423739-B | Improved enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts and additives | 拜耳公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-114514223-B | Process for enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines comprising using novel iridium catalysts | 拜耳公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2024041976-A1 | PROCESS FOR DISTILLATIVE RECOVERY OF 1,1,1,3,3,3-HEXAFLUORO-2-PROPANOL (HFIP) FROM MIXTURES WITH 4- SUBSTITUTED 1,2,3,4-TETRAHYDROQUINOLINES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-29 | — | — | WO | disclosed |
| CN-111902399-B | Enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts | 拜耳公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-3774735-B1 | ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST | BAYER AG (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-4112602-A1 | ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST | Bayer Aktiengesellschaft (DE) | 2023-01-04 | — | — | EP | disclosed |
| EP-4034528-A1 | PROCESS COMPRISING THE USE OF NEW IRIDIUM CATALYSTS FOR ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES | Bayer Aktiengesellschaft (DE) | 2022-08-03 | — | — | EP | disclosed |
| CN-114514223-A | Process comprising enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines using a novel iridium catalyst | 拜耳公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-114423739-A | Improved enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts and additives | 拜耳公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2021058458-A1 | PROCESS COMPRISING THE USE OF NEW IRIDIUM CATALYSTS FOR ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-01 | — | — | WO | disclosed |
| CN-1264839-C | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-19 | — | — | CN | disclosed |
| US-20050240035-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005066131-A1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| US-6894177-B2 | Intermediate compounds of non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2005-05-17 | — | — | US | disclosed |
| CN-1494545-A | Non-nucleoside reverse transcriptase inhibitors | ά | 2004-05-05 | — | — | CN | disclosed |
| US-6716850-B2 | ESPECIALLY N-(NITROGEN HETEROAR-2-YL)-SUBSTITUTED TETRAHYDROCYCLOPROPA(C)CHROMEN-1-UREAS AND THIOUREAS; TREATING HIV-1, PARTICULARLY A DRUG ESCAPE MUTANT. | MEDIVIR AB (SE) | 2004-04-06 | — | — | US | disclosed |
| US-20030187266-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| US-20030069224-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2003-04-10 | — | — | US | disclosed |
| US-5627192-A | ANTILIPEMIC AGENTS, ANTICHOLESTEROL AGENTS OR ANTIOXIDANTS | BRISTROL-MYERS SQUIBB COMPANY (US) | 1997-05-06 | — | — | US | disclosed |
| US-5411969-A | Antihyperlipidemic/antioxidant dihydroquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240035-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, TYMP, PNP | NOTUM 712/4885HSD17B3 1010/4885P2RX4 3655/4885 |
| US-20030069224-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, NAT10, NSUN2 | NOTUM 848/4885HSD17B3 949/4885P2RX4 4775/4885 |
| US-20030187266-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, NAT10, NSUN2 | NOTUM 848/4885HSD17B3 949/4885P2RX4 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.